GSK's JAK1 doubts raise questions for drug class
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's reasoning behind its decision to drop development of its Phase II JAK1 inhibitor GSK2586184 (solcitinib) in three diseases raises questions over the future of other pure JAK1 inhibitors in development.